Pharming (PHAR) Revenue (2020 - 2026)
Pharming's (PHAR) quarterly Revenue came in at $162.7 million in Q2 2026, up 94396789.42% YoY from N/an in Q2 2025, and up 224522754565306.4% on a QoQ basis from $0.0 in Q1 2026.
Pharming (PHAR) Revenue (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Revenue data on file, last reported at $162.7 million in Q2 2026.
- Quarterly Revenue rose 94396789.42% year-over-year to $162.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $366.5 million (up 363.32% YoY) and the FY2025 annual result came in at $376.1 million, up 26.56% from the prior year.
- Revenue climbed to $162.7 million in Q2 2026, from $0.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $54900.0 billion in Q2 2023 to a low of $0.0 in Q1 2026.
- A 5-year average of $3050.1 billion and a median of $54.9 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2025 — Revenue jumped 130080113.9% — and 2026, when it slumped 100.0%.
- Tracing PHAR's Revenue over 5 years: stood at $151.0 million in 2022, then sank by 100.0% to $81.2 in 2023, then soared by 151.85% to $204.5 in 2024, then surged by 52078139.61% to $106.5 million in 2025, then surged by 52.73% to $162.7 million in 2026.
- The last three Revenue figures came in at $162.7 million (Q2 2026), $0.0 (Q1 2026), and $106.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 162.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.66 Mn |
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 106.50 Mn |
| Sep 30, 2025 | 97.30 Mn |
| Jun 30, 2025 | 172.32 |
| Mar 31, 2025 | 79.09 Mn |
| Dec 31, 2024 | 204.50 |
| Sep 30, 2024 | 74.80 |
| Jun 30, 2024 | 129.68 Mn |
| Mar 31, 2024 | 55.59 Mn |
| Dec 31, 2023 | 81.20 |
| Sep 30, 2023 | 66.66 Mn |
| Jun 30, 2023 | 54,900.00 Bn |
| Mar 31, 2023 | 42.54 Mn |
| Dec 31, 2022 | 151.00 Mn |
| Sep 30, 2022 | 54.20 Mn |
| Jun 30, 2022 | 50.10 Mn |
| Mar 31, 2022 | 46.60 Mn |
| Dec 31, 2021 | -139.30 Mn |
| Sep 30, 2021 | 52.63 Mn |